UA138212U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), the content of thrombomodulin, folic acid, C-reactive protein (SRP), β-transforming growth 677-TT, 786-CC and levels of thrombomodulin> 5 ng / ml, folic acid <6 ng / ml, PSA> 6 mg / l, ΤΦΡ-β1 <14 ng / ml predict the development of osteoarthritis.

Description

A useful model belongs to medicine, in particular to orthopedics and rheumatology, and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include radiography, examination of a biopsy of the synovial membrane, synovial fluid, a biopsy of cartilage (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196).

The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The set task is solved by the fact that, in addition to clinical examination and radiography, polymorphism of methylenetetrahydrofolate reductase genes (MTNEV) is determined in the patient's blood serum

Сб677Т), nitric oxide synthase (6еМО5 17860), content of thrombomodulin, folic acid, C-reactive protein (CRP), transforming growth factor beta 1 (TGF-DVI). With homozygous carrier 677-TT, 786-SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, SRP "6b mg/l, TFR-B1 "14 ng/ml predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, X-rays are taken, the polymorphism of MTNEV C677T, eMmo5 T786C genes is determined, the content of thrombomodulin, folic acid, SRP, TFR-VI1 is determined by the immunoenzymatic method. With homozygous carrier 677-TT, 786-SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, SRP "b mg/l, TFR-VDI "14 ng/ml predict the development of osteoarthritis.

A specific example of using the method

Patient A., 63 years old, was hospitalized in the clinic due to pain in the left knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. The polymorphism of MTNEV C677T and emo5 17860 genes was determined in blood serum. The content of thrombomodulin, folic acid, SRP, TGF-DVI was determined by immunoenzymatic method. A homozygous carrier of 677-TT and 786-SS was established, the levels of thrombomodulin - 15 ng/ml, folic acid - 2.8 ng/ml, SRP - 19 mg/l, TGF-VI - 6.8 ng/ml. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, X-ray photography, which is distinguished by the fact that, in addition, in the patient's blood serum, the polymorphism of the genes methylenetetrahydrofolate reductase (МТНЕВ С677Т), nitric oxide synthase (ЕМО5 1786С), the content of thrombomodulin, folic acid, C-reactive protein ( SRP), transforming growth factor beta 1 (TGF-VDI) and with homozygous carrier 677-TT, 786-SS and levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, SRP "b mg/l, TGF- VI "14 ng/ml predict the development of osteoarthritis.